JG
AKBA icon

Jefferies Group’s Akebia Therapeutics AKBA Stock Holding History

Jefferies Group’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-38,039
Closed -$184K – 2672
2019
Q2 		$184K Buy
38,039
+17,372
+84% +$98.8K ﹤0.01% 2161
2019
Q1 		$169K Sell
20,667
-22,004
-52% -$151K ﹤0.01% 1988
2018
Q4 		$236K Buy
42,671
+20,856
+96% +$163K ﹤0.01% 1748
2018
Q3 		$193K Sell
21,815
-11,685
-35% -$105K ﹤0.01% 2118
2018
Q2 		$334K Buy
+33,500
New +$335K ﹤0.01% 1803
2015
Q4 		– Sell
-16,600
Closed -$160K – 2242
2015
Q3 		$160K Buy
+16,600
New +$152K ﹤0.01% 1976

Other funds holding AKBA

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jefferies Group's AKBA Position: Q3 2019 in Review

Jefferies Group sold out of Akebia Therapeutics (AKBA) in Q3 2019, closing a stake of 38,039 shares — an estimated $184K sold.

Jefferies Group first reported a position in AKBA in Q3 2015 and held it in 6 quarters. The position peaked at $334K in Q2 2018. 150 funds tracked by Wall St. Rank hold AKBA as of Q3 2019.

  • Jefferies Group reported no remaining Akebia Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Jefferies Group sold 38,039 Akebia Therapeutics shares in Q3 2019, an estimated $184K.
  • Jefferies Group first reported a position in Akebia Therapeutics in Q3 2015 and held it in 6 quarters.
  • Jefferies Group's Akebia Therapeutics position peaked at $334K in Q2 2018.
  • 150 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q3 2019.

Based on Jefferies Group's 13F filing for Q3 2019, filed 13 Nov 2019.